News January 25th or 26th? Maybe Arqule will take the opportunity to announce the HCC results here at the 16th JFCR－ISCC conference. http://iscc.umin.jp/2011.html Two presentations that include ARQ-197 are as follows:
1) Haruyasu Murakami (Shizuoka Cancer Center)
The effect of CYP2C19 polymorphism on the tolerability of ARQ 197: Results from phase 1 trial in Japanese patients with metastatic solid tumors
2) Brian Schwartz (Arqule Inc)
Discovery and Development of Tivantinib, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Solid Tumors.